# Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients

Source: https://onco.cc/trials/nct03874026/  
OnCo record `nct03874026` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by National Cancer Institute, Naples, now recruiting.

## Summary

Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients is a phase 2, interventional study registered as NCT03874026 by National Cancer Institute, Naples, with a registry enrolment figure of 34 participants, started 2019-09-05 and due to reach its primary completion in 2023-05-19. Interventions recorded: Folfiri/Cetuximab. Conditions listed: Colorectal Cancer; ADCC. Primary outcome: Activity. Colorectal eligibility wording from the registry: "* Cytological or histological diagnosis of colorectal adenocarcinoma;". Sites: Italy. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: CIFRA
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT03874026
- Phase: 2
- Setting: Cetuximab, Irinotecan and Fluorouracile in FiRst-line Treatment of Immunologically-selected Advanced Colorectal Cancer Patients: the CIFRA Study
- Sponsor: National Cancer Institute, Naples
- Enrolled: 34

## Sources

- ClinicalTrials.gov NCT03874026: https://clinicaltrials.gov/study/NCT03874026

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct03874026.json